WE! are the clinical research

Board member of the European Patients Forum EPF and the Polish Association of Patients with Phenylketonuria and Rare Diseases Ars Vivendi. Expert of the Federation of Polish Patients (FPP) for the evaluation, management, and implementation of projects financed from EU and national funds.

Expert of the European Institute of Technology (EIT) at the European Parliament. A graduate of the European Patients' Academy EUPATI and the coordinator of the Polish EUPATI Platform, aimed at spreading knowledge about clinical trials from the patient's point of view. Experienced trainer and educator.

Co-organizer of numerous conferences, webinars, events for patients and other stakeholders of the health care system. Propagator of "patient involvement" and "patient centricity" - an approach that takes into account the patient's perspective, his welfare, individual preferences and enabling him to co-decide in all procedures and medical activities. Co-author of patient information booklets on selected rare diseases.

Involved in the development of European programs for the creation, storage, sharing, and protection of sensitive patients' data. Member of the Patient Group Committee in the Data Saves Lifes initiative led by EPF and the European Institute for Innovation through Health Data i-HD.
 

Director and member of the research team of the LexMedica Clinical Research Center in Wrocław. Associated with the medical industry for over 20 years. In her work, she was already responsible for several dozen research projects, mainly in the area of chronic intestinal diseases, urological and rheumatological diseases. She collaborates with many leaders in the clinical research industry. She graduated from the Medical University with a specialization in Medical Analytics and Management at the University of Economics in Wrocław. She also gained her experience in well-known companies from the pharmacological industry.
For two years she has been conducting educational activities for chronically ill patients. She has direct contact with the patient, which distinguishes her from the owners of large medical centers. She knows the Patient's problems and therefore knows how to talk to them.

Clinical research enthusiast associated with the industry since 1998. She is a graduate of the Second Faculty of Medicine at the Medical University of Warsaw. In her professional career to date, working in CRO companies, she has developed skills in the field of monitoring and management of clinical trials of phases I-IV, in many therapeutic indications.
Since 2005, she has been working for PPD Poland, a global company in the CRO sector, currently as the Deputy Director for Clinical Operations. Responsible for supervising and managing the clinical trial monitors team, training the clinical team, developing the network of partner centers, and cooperating with patient organizations. Vice-president of the GCPpl Association, involved in the activities of the Association since 2002. Co-organizer of statutory activities such as training and industry meetings, including annual conferences on the occasion of the International Day of Clinical Research and the educational program for patients, Clinical Research Ambassadors.
She has many years of experience as a lecturer in postgraduate studies and as a speaker at industry conferences in the field of clinical trials. Author and co-author of articles and books on clinical trials. She is a member of the Polish EUPATI Platform (European Patients' Academy). She supports the activities of patient organizations by participating in meetings and training sessions for patients. She cooperates with the Medical Research Agency, including in creating the portal "Patient in clinical trials". 

Dan Lewi is Head of Business Development and Patient Advocacy at Pulse Infoframe, is the founder of the rare disease charity The Cure & Action for Tay-Sachs (CATS) Foundation in the UK and is also the chairman of the European Tay-Sachs and Sandhoff Charity Consortium (ETSCC). His unique experience in the MedTech sector is combined with over 10 years in the advocacy sector meaning that Dan is fully aware of the patient voice and is able to always put them at the forefront of the discussion in relation to the development of clinical studies. 
Having set up The CATS Foundation in 2011 after his daughter Amélie was diagnosed with Tay-Sachs, Dan has been instrumental in driving forward the research for the disease. In 10 years, he has helped bring various gene therapy, drug repurposing and small molecule programmes for the disease into the clinic.
 

A graduate of the Warsaw University (Faculty of Chemistry), the Medical University of Gdańsk and the Gdańsk Foundation for Management Development (Clinical Research Management).
For 21 years associated with the pharmaceutical industry, and 19 years within clinical research. Responsible for the management, organization and conduct of clinical trials in different specialist, managerial and director positions in pharmaceutical and global CRO companies. Currently, for over four years professionally associated with Pharmaceutical Product Development (PPD), where as a Project Director and Oversight Director is responsible for managing global programs and clinical projects as well as relationships with key clients.
Perfectly understands the clinical research field. Has almost two decades of extensive professional experience in managing multidisciplinary research teams in various therapeutic indications. Subject Matter Expert in the field of pediatric research and rare diseases. Currently, co-creates a global training program for pediatric and rare disease studies. Is passionate about modern and innovative methods of patient recruitment and cooperation with global patient organizations. An Expert of the Medical Research Agency in Poland.
A long-time educator in the field related to the management of clinical trials, recruitment strategies, clinical trials in pediatrics and rare diseases. Speaker at local and international industry conferences and courses. Member of GCP PL, ACRP, PMI and PIPMG.
Like Steve Jobs believes that "The only way to do a good job is to love what you do"

Since 2009 Marta Chodorek has covered various Business Development roles, including technology and consultancy within the Life Science sector. She is very enthusiastic and passionate about  driving the new generation of clinical trial processes to improve human health and save lives.
Using her vast experience across the sector she is very happy to get involved in knowledge sharing and bringing like-minded people together to support Research in Human health. For the past 3 years, she has been working for TriNetX, a leading global patient data network that supports data driven feasibility, design & recruitment as well as other scientific research. Within her role she engages healthcare organisations for this network and supports RWE (Real World Evidence) projects together with Scientists to facilitate their day to day research and to help them gain better insides as well as enabling faster decision making

29 lat doświadczenia w praktyce klinicznej, specjalista chorób wewnętrznych i farmakologii klinicznej z tytułem doktora nauk medycznych. Tytuł MBA zdobyty na University of Wales.
21 lat doświadczenia w badaniach klinicznych, od badań wczesnych faz do fazy IIIb. Główny badacz w 40 badaniach klinicznych.
Dyrektor medyczny i lider w globalnych firmach CRO.

ex-GSK and CEO of MeRaD pharmaceuticals

Dr. Raj Kumar is the Chief Medical officer and Founder of MeRaD Pharmaceuticals and co-founder of PharmaCambridge, Camnord and ArcezaPharma. 
He is a graduate in Medicine and Surgery from the Universities of Dundee (M.B. ChB), and a graduate of University of London (BSc.) and obtained his post-graduate diploma in psychiatry and neurology from the Royal College of Surgeons in Ireland. (D.P.M)
Following a successful academic and clinical career, Raj joined SmithKline Beecham's Department of Human Pharmacology gaining experience in early phase drug development and experimental medicine including first in man studies. Subsequently, he joined the International Clinical Development Team as Director of Psychiatry and focused upon late-stage drug development, culminating in his role as VP and Director for US NeuroSciences and Gastroenterology, Clinical Development and Medical affairs. During this time, his team focused on the life-cycle management of Paxil resulting in its emergence as a billion-dollar product. Post-merger with Glaxo, Raj became VP and Global Head of Psychiatry.  This included experience with biomarkers and surrogate markers, including EEG and MRI and psychometric batteries.
Raj has extensive experience of regulatory affairs, in Japan, India, Africa, Europe and North America, having successfully submitted a number of NDA’s, ANDA, CTA’s and IND as well face to face interaction with these agencies on scientific advice and both pre-IND and pre-NDA meetings.
On a move to Ranbaxy Laboratories, Raj served as President of R&D. Followed by President of Research and Development and Commercialization for NCE’s at Dr. Reddy’s Laboratories, Hyderabad India.  Raj has extensive experience in drug development, regulatory affairs, project management, Quality Management Systems and commercial strategy in North America, Europe, Japan, and Asia.
Dr Kumar is a Fellow of the Royal Society of medicine and was a Fellow of the Institute of Directors UK. He was a visiting Professor at the University of Hyderabad. He has published extensively and has presented clinical and scientific research at both international and national forums He also served as a committee member for The Wellcome Trust for affordable health care fund for three years.  Raj is a guest lecturer for the MBE/ MPhil course at the Institute of Biotechnology, University of Cambridge.  Raj also serves as a Trustee for Multiple-Sclerosis- Shift UK, as well as a Governor at Cambridge Regional College.

Katarina Pavlovic is assistant professor at the Faculty for project and innovation management in Belgrade, Serbia. She is a graduated biochemist with PhD in Quality management. She is especially attached to pharmaceutical sector as she started her career in a big pharmaceutical company in Serbia where she acquired knowledge and experience giving her the opportunity for advancement later on. 
With over 20 years now of industrial experience and four years of experience in academia, she connects science with her expertise in business topics reaching targeted results. 
Dr Pavlovic teaches introductory and upper-level courses in General Management, Contemporary Management, Project Management, Risks in Project Management, Knowledge and Innovation Management and Change Management with profound emphasis on fostering students’ commitment to learning and contribution to different aspects of business activities. Her major scientific research interests are in specificities of Agile transformation of businesses, application of methodologies of Knowledge and Innovation management, contribution of different aspects of leadership to overall business objectives and more.  
She has thorough experience with strategy and business development along with innovation as a parameter for development and competitiveness. In consulting services, she addresses the issues of corporate growth, changing market conditions, capital requirements and investment options, risk mitigation, agile and business model transformation, learning and leadership. Her portfolio of consulting services includes 39 companies.

Professor Anna David is consultant in obstetrics and maternal/fetal medicine at UCLH. Joining University College London (UCL) in 2000 from Queen Charlotte’s Hospital, Professor David was awarded a PhD for her work on fetal gene therapy for treatment of early onset genetic disease in 2005. She then trained in maternal fetal medicine at UCLH under professor Charles Rodeck. In 2008 she was awarded a prestigious UK HEFCE/Department of Health funded senior clinical lectureship in women’s health at UCL and UCLH when she took up a consultant post. 
Anna offers a range of diagnostic and therapeutic services in the fetal medicine unit at UCLH. She specialises in cases where the baby has a structural anomaly, a genetic condition or when the baby’s growth is poor (fetal growth restriction). She has close links with the talented UCLH neonatal team that are expert in caring for the smallest preterm infants. 
Professor David set up the preterm birth clinical service at UCLH in 2008, which is now one of the busiest in the UK, providing continuity of care in a nurturing environment. The comprehensive service offers pre-conceptual counselling, a wide range of cerclage and other treatments and predictive tests. She is research lead at the Centre for Prenatal Therapy, the team who performed the first fetal surgery for spina bifida in the UK in 2018. 
Professor David is director of the EGA Institute for Women's Health, UCL. Her team are developing new treatments for fetal growth restriction using maternal gene therapy, and is pioneering the first clinical trial of in utero stem cell transplantation for brittle bone disease. She has won awards for her mentorship of academic trainees and colleagues, and is a fellow of the Royal College of Obstetricians and Gynaecologists.
 

Researcher at the Medical University of Warsaw, Department of Medical Biology, Faculty of Health Sciences, head of the University Laboratory of Research on Feminine Milk and Lactation at the Regional Milk Bank at the Specialist Hospital. St. Families in Warsaw.
Associate of the Medical Research Agency, Secretary of the Scientific Working Group at the President of ABM. A graduate of Kozminski University in the field of Conducting and Organization of clinical trials. President and co-founder of the Foundation of the Bank of Women's Milk, established in 2010, acting as an expert and patient organization popularizing knowledge about human milk banks and the way such institutions operate in Poland and abroad.
Winner of the prestigious award of the Minister of Science and Higher Education (2019) for outstanding scientific and scientific and technical achievements in the category of research for the benefit of society (2018).
During the COVID-19 pandemic, together with a nationwide team, she undertook research on the risk of infection of a child from a mother suffering from COVID-19 and the safety of the COVID-19 vaccine in the perinatal period.
 

MRCOG

Born in Warsaw, attended Warsaw Medical University which graduated Physician in 1999. Soon after completing internship started her specialty training in the Second Department of Obstetrics and Gynaecology at Duchess Anna Mazowiecka Hospital in Warsaw with special interest in Maternal and Fetal medicine. 

After moving to UK spent some time as Research Fellow in Harris Birthright Centre at Kings College Hospital mastering her ultrasound skills. Appointed as Specialty Doctor at University College London Hospital in 2014 in their Maternal and Fetal Assessment Unit, became active in audit and research studies addressing high risk pregnancy management. Presented her work on several conferences and professional meetings. Teaching, in form of lectures and seminars as well as everyday bedside practical work with students, is prominent part of her professional activity.

Since 2017 took a role of Maternal and Fetal Medicine Research Fellow in Fetal Medicine Unit of University College London Hospital with special interest in Intrauterine growth restriction. Is member of EVERREST Consortium, international group developing treatment for fetuses affected by early onset severe intrauterine growth restriction. Currently PhD student at University College London concentrating on biophysical and molecular changes of the maternal-placental-fetal circulation and placentation in pregnancies affected by intrauterine growth restriction. Member of multidisciplinary research team.

A three-time graduate and lecturer at Kozminski University.
He has been associated with the research market since the nineties. It deals with the activities of Research Centers as well as recruitment and retention centers. Co-founder of the Osteomed Medical Center and the Lambda Clinical Research Center. An expert in planning and implementing campaigns of candidates in the recruitment with an understandable understanding of the correction and correctness of the language. In the years 2012 - 2019, the Head of Patient Engagement at Synexus and currently the Head of the Clinical Research Department at the CMP Medical Center.

Multiple speakers at international recruitment conferences.

Deloitte UK’s Centre for Health Solutions

Maria João Cruz is an Assistant Research Manager for The UK Centre for Health Solutions, the independent research hub of Deloitte’s Health Care and Life Sciences teams. At the Centre, she conducts rigorous analysis and research to generate insights that support the practice across life sciences and health care. 

Maria João has co-authored reports that explore the role of artificial intelligence in the digital transformation of biopharma’s value chain, including Intelligent clinical trials and Intelligent drug supply chains. Since joining the team, Maria João has also contributed to the series of annual reports, Measuring the return from pharmaceutical innovation, which tracks the productivity of late-stage clinical development of various biopharma companies and identifies key solutions that can help ensure a sustainable future for biopharma R&D. 

Maria João has a PhD in Bioengineering and over 10 years of experience in scientific research.

Deloitte UK’s Centre for Health Solutions

Karen established Deloitte UK’s Centre for Health Solutions in November 2011. The Centre is the independent research arm of Deloitte’s Life Sciences and Health Care (LSHC) practices, providing a trusted source of relevant, timely and reliable insights on emerging trends, challenges, and solutions. The Centre combines creative thinking, robust research, and industry experience to develop evidence-based perspectives on some of the biggest and most challenging issues facing our life sciences and healthcare clients to help them to improve their efficiency and cost-effectiveness and, importantly, benefit the patient. 

Recent reports with a life sciences focus include our series of reports on how AI is transforming the biopharma value chain, with separate reports on Intelligent drug discovery, Intelligent clinical trials, and Intelligent drug supply chains. All these reports focus on how innovation and advanced technologies are transforming care delivery and people’s experience of care. Her recent healthcare reports include: Digital Transformation: Shaping the future of European healthcare, Realising digital first primary care and Closing the digital gap: Shaping the future of UK healthcare. Over the past few weeks Karen has launched series of predictions from her team’s report ‘The future unmasked: Predicting the future of healthcare and life sciences in 2025’; the full report is available from the 9th December 2020.

In addition to reports, Karen presents her research at numerous sector and client conferences and events and publishes a weekly blog which since March has been focused on various issues relating to the impact of COVID-19 on LSHC (https://blogs.deloitte.co.uk/health/). She also provides a weekly update on public health on Deloitte’s COVID-19 fortnightly webinar.   

Karen is a member of the Institute of Chartered Public Finance and Accountants and has extensive experience in leading research into healthcare and life-science issues in the UK and internationally.  In 2002, Karen received an OBE for her work on Health Value for Money Audit work. Since 2011, Karen has been a Non-Executive Director at Dartford and Gravesham NHS Trust where she chairs the Audit Committee.

Aleksandra Przegalińska-Skierkowska received her PhD in the philosophy of artificial intelligence at the Department of Cultural Philosophy of the Institute of Philosophy of the University of Warsaw. Currently, she is an assistant professor at the Center for Research on Organizations and Workplaces at the Kozminski University. Currently, she conducts research at the Massachusetts Institute of Technology in Boston. A graduate of The New School for Social Research in New York, where she participated in research on identity in virtual reality, with particular emphasis on Second Life. She is interested in the development of new technologies, especially green and sustainable technologies, humanoid artificial intelligence, social robots, and wearable technologies.